Corticosteroides Injetáveis em Patologia Músculo-Esquelética: Uma Revisão Narrativa

Patrícia Cruz, Alexandre Camões

Resumo


As queixas do foro músculo-esquelético assumem um lugar importante nos motivos de consulta dos cuidados de saúde primários. Corticosteroides injetáveis sintetizados (CCT) têm sido amplamente utilizados como agentes anti-inflamatórios em várias patologias músculo-esqueléticas, quer articulares quer de tecidos moles, possibilitando um maior controlo sintomático, uma maior amplitude de movimento e/ou melhoria da função. A eficácia na sua utilização depende não só de um correto diagnóstico médico, como também da seleção do fármaco mais adequado e da própria execução técnica do procedimento. Atualmente existem poucas evidências para orientar a seleção do CCT mais indicado. Este artigo de revisão oferece uma visão global das diferentes preparações de CCT que podem ser utilizados em procedimentos injetáveis em patologia músculo-esquelética, das suas indicações e complicações de forma a auxiliar o médico na escolha do melhor fármaco. A escolha deve ser orientada pelo objetivo, pelo diagnóstico músculo-esquelético subjacente e pela experiência clínica. As complicações decorrentes do seu uso são raras, mas o médico deve estar alerta e compreender os seus potenciais riscos, de forma a aconselhar apropriadamente o doente.


Palavras-chave


Corticosteroides/administração e dosagem; Corticosteroides/uso terapêutico; Doenças Musculoesqueléticas/tratamento farmacológico; Injeções Intra-Articulares

Texto Completo:

PDF

Referências


Dooley P, Martin R. Corticosteroid Injections and Arthrocentesis. Can Fam Phys. 2002; 48:285-8.

Freire V, Bureau NJ. Injectable corticosteroids: take precautions and use caution. Semin Musculoskelet Radiol. 2016;20:401-8. doi: 10.1055/s-0036-1594286.

Hollander JL, Brown EM, Jessar RA, et al. Hydrocortisone and cortisone injected into arthritic joints comparative effects of and use of hydrocortisone as a local antiarthritic agent. JAMA. 1951; 147:1629-35.

Stephens MB, Beutler AI, O’Connor F. Musculoskeletal Injections: A review of the Evidence. Am Fam Phys. 2008; 78:971-6.

Monseau AJ, Nizran PS. Common injections in musculoskeletal medicine. Prim Care. 2013;40:987-1000, ix-x. doi: 10.1016/j.pop.2013.08.012.

Ramamoorthy S, Cidlowski JA. Corticosteroids: mechanisms of action in health and disease. Rheum Dis Clin North Am. 2016; 42:15–31, vii. doi:

1016/j.rdc.2015.08.002.

Ostergaard M, Halberg P. Intra-articular corticosteroids in arthritic disease: a guide to treatment. BioDrugs. 1998; 9:95–103.

Barnes PJ. Anti-inflammatory actions of glucocorticoids: molecular mechanisms. Clin Sci. 1998; 94:557–72.

Silva RM. Infiltrações e punções em traumatologia do desporto. Rev Med Desp In Forma. 2010; 1:29-30.

Peñas CF, Nijs J. Trigger point dry needling for the treatment of myofascial pain syndrome: current perspectives within a pain neuroscience paradigm. J Pain Res. 2019; 12: 1899–911. doi: 10.2147/JPR.S154728.

Genovese MC. Joint and Soft-Tissue Injection. Postgrad Med. 1998; 103:125-33.

Wittich CM, Ficalora RD, Beckman TJ. Musculosketal Injection. Mayo Clin Proc. 2009; 84: 831–7.

MacMahon PJ, Eustace SJ, Kavanagh EC. Injectable Corticosteroid and Local Anesthetic Preparations: A Review for Radiologists. Radiology. 2009, 253:647-61.

Raynauld JP, Buckland-Wright C, Ward R, Choquette D, Haraoui B, Martel-Pelletier J, et al. Safety and efficacy of long-term intraarticular steroid injections in osteoarthritis of the knee: a randomized, double-blind, placebocontrolled trial. Arthritis Rheum. 2003; 48:370–7. doi: 10.1002/art.10777.

Cole BJ, Schumacher HR Jr. Injectable corticosteroids in modern practice. J Am Acad Orthop Surg. 2005; 13:37–46.

Benzon HT, Gissen AJ, Strichartz GR, Avram MJ, Covino BG. The effect of polyethylene glycol on mammalian nerve impulses. Anesth Analg. 1987;

:553–59.

Shah K, Watson D, Campbell C, Meek RM. Intra-articular injection composed of steroid, iohexol and local anaesthetic: is it stable? Br J Radiol. 2009; 82:109–11.

Nichols AW. Complications associated with the use of corticosteroids in the treatment of athletic injuries. Clin J Sport Med. 2005; 15:370–5.

Schetman D, Hambrick GW Jr, Wilson CE. Cutaneous changes following local injection of triamcinolone. Arch Dermatol. 1963; 88:820–8.

Ostergaard M, Halberd P. Intra-articular corticosteroid in arthritic disease: a guide to treatment. BioDrugs .1998; 9:95-103.

Kondo T, Kitazawa R, Yamaguchi A, Kitazawa S. Dexamethasone promotes osteoclastogenesis by inhibiting osteoprotegerin through multiple levels. J Cell Biochem. 2008; 103:335–45.

Foremny GB, Pretell-Mazzini J, Jose J, Subhawong TK. Risk of bleeding associated with interventional musculoskeletal radiology procedures. A comprehensive review of the literature. Skeletal Radiol. 2015; 44:619–27.

Shah A, Mak D, Davies Mark, James SL, Botchu R. Musculoskeletal Corticosteroid Administration: Current Concepts. Can Assoc Radiol J. 2019;70:29-36. doi: 10.1016/j.carj.2018.11.002.

Speed CA. Injection therapies for soft-tissue lesions. Best Pract Res Clin Rheumatol. 2007;21:333-47. doi: 10.1016/j.berh.2006.11.001.

Brinks A, Koes BW, Volkers AC, Verhaar JA, Bierma-Zeinstra SM. Adverse effects of extra-articular corticosteroid injections: a systematic review. BMC Musculoskelet Disord. 2010; 11:206. doi: 10.1186/1471-2474-11-206.

Gray RG, Gottlieb NL. Intraarticular corticosteroids: an update assessment. Clin Orthop.1983; 177:235–63.

Fitzgerald RH. Intrasynovial injection of steroids: uses and abuses. Mayo Clin Proc. 1976; 51:655–9.

Hollander JL. Intraarticular hydracortisone therapy in arthritis and allied conditions. J Bone Joint Surg Am. 1953; 35:983–90.

Weston VC, Jones AC, Bradbury N, Fawthrop F, Doherty M. Clinical features and outcome of septic arthritis in a single UK Health District 1982–1991. Ann Rheum Dis. 1999; 58:214–9.

Youssef J, Novosad SA, Winthrop KL. Infection risk and safety of corticosteroid use. Rheum Dis Clin North Am. 2016;42:157-76, ix-x. doi: 10.1016/j.rdc.2015.08.004.

Ostensson A, Geborek P. Septic arthritis as a non-surgical complication in rheumatoid arthritis: relation to disease severity and therapy. Br J Rheumatol. 1991; 30:35–8.

Schumacher HR Jr. Aspiration and injection therapies for joints. Arthritis Rheum. 2003;49:413-20. doi: 10.1002/art.11056.

Emkey RD, Lindsay R, Lyssy J, Weisberg JS, Dempster DW, Shen V. The systemic effect of intraarticular administration of corticosteroid on markers of bone formation and bone resorption in patients with rheumatoid arthritis. Arthritis Rheum. 1996; 39:77-82. doi: 10.1002/art.1780390215.

Roberts WN, Babcock EA, Breitbach SA, Owen DS, Irby WR. Corticosteroid injection in rheumatoid arthritis does not increase rate of total joint arthroplasty. J Rheumatol. 1996; 23:1001-4.

Balch HW, Gibson JM, El-Ghobarey AF, Bain LS, Lynch MP. Repeated corticosteroid injections into knee joints. Rheumatol Rehabil. 1977; 16:137–40.

Driban J, Lavalley MP, Price LL, Harvey WF, McAlindon TE. Intra-articular corticosteroids are safe and have no major effect on structural progression of synovitic knee OA: a 2-year randomized controlled trial of 3-monthly triamcinolone hexacetonide. Arthritis Rheum. 2015; 67.

Coombes BK, Bisset L, Vicenzino B. Efficacy and safety of corticosteroid injections and other injections for management of tendinopathy: a systematic review of randomised controlled trials. Lancet. 2010; 376:1751-67. doi: 10.1016/S0140-6736(10)61160-9.

DiStefano V, Nixon JE. Steroid-induced skin changes following local injection. Clin Orthop Relat Res. 1972; 87:254 –6.

Place VA, Velazquez JG, Burdick KH. Precise evaluation of topically applied cortico- steroid potency: modification of the Stoughton-McKenzie assay. Arch Dermatol. 1970; 101:531–7.

Newman BA, Feldman FF. The topical and systemic use of cortisone in dermatology. Calif Med. 1951; 75:324 –31.

Basadonna PT, Rucco V, Gasparini D, Onorato A. Plantar fat pad atrophy after corticosteroid injection for an interdigital neuroma: a case report. Am J Phys Med Rehabil. 1999; 78:283–5.

Iuel J, Kryger J. Local cutaneous atrophy following corticosteroid injection. Acta Rheumatol Scand. 1965; 11:137–44.

Cassidy JT, Bole GG. Cutaneous atrophy secondary to intra-articular corticosteroid administration. Ann Intern Med.1966; 65: 1008 –18.

Jacobs MB. Local subcutaneous atrophy after corticosteroid injection. Postgrad Med. 1986; 80:159 –60.

Lund IM, Donde R, Knudsen EA. Persistent local cutaneous atrophy following corticosteroid injection for tendinitis. Rheumatol Rehabil. 1979; 18:91–3.

Rogojan C, Hetland ML. Depigmentation: a rare side effect to intra-articular glucocorticoid treatment. Clin Rheumatol. 2004; 23:373–5.

Kligman AM, Willis I. A new formula for depigmenting human skin. Arch Dermatol. 1975; 111:40–8.

Chen SK, Lu CC, Chou PH, Guo LY, Wu WL. Patellar tendon ruptures in weight lifters after local steroid injections. Arch Orthop Trauma Surg. 2009; 129:369–72.

Bjorkman A, Jorgsholm P. Rupture of the extensor pollicis longus tendon: a study of aetiological factors. Scand J Plast Reconstr Surg Hand Surg. 2004; 38:32–5.

Dean BJ, Lostis E, Oakley T, Rombach I, Morrey ME, Carr AJ. The risks and benefits of glucocorticoid treatment for tendinopathy: a systematic review of the effects of local glucocorticoid on tendon. Semin Arthritis Rheum. 2014; 43:570–6.

Scutt N, Rolf CG, Scutt A. Glucocorticoids inhibit tenocyte proliferation and tendon progenitor cell recruitment. J Orthop Res. 2006; 24:173–82.

Haraldsson BT, Langberg H, Aagaard P, Zuurmond AM, van El B, Degroot J, et al. Corticosteroids reduce the tensile strength of isolated collagen fascicles. Am J Sports Med. 2006; 34:1992–7. doi: 10.1177/0363546506290402.

Berger RG, Yount WJ. Immediate “steroid flare” from intraarticular triamcinolone hexacetonide injection: case report and review of the literature. Arthritis Rheum. 1990; 33:1284–6.

Young P, Homlar KC. Extreme postinjection flare in response to intraarticular triamcinolone acetonide (Kenalog). Am J Orthop. 2016; 45:E108–E11.

Gilsanz V, Bernstein BH. Joint Calcification following intra-articular corticosteroid therapy. Radiology. 1984; 151:647-9.

Habib G, Jabbour A, Artul S, Hakim G. Intra-articular methylprednisolone acetate injection at the knee joint and the hypothalamic-pituitary-adrenal axis: a randomized controlled study. Clin Rheumatol. 2014; 33:99–103.

Duclos M, Guinot M, Colsy M, Merle F, Baudot C, Corcuff JB, et al. High risk of adrenal insufficiency after a single articular steroid injection in athletes. Med Sci Sports Exerc. 2007; 39:1036–43. doi: 10.1249/mss.0b013e31805468d6.

Everett CR, Baskin MN, Speech D, Novoseletsky D, Patel R. Flushing as a side effect following lumbar transforaminal epidural steroid injection. Pain Phys. 2004; 7:427–9.

Habib GS, Bashir M, Jabbour A. Increased blood glucose levels following intra-articular injection of methylprednisolone acetate in patients with controlled diabetes and symptomatic osteoarthritis of the knee. Ann Rheum Dis. 2008; 67:1790–1.

Mens JM, Nico de Wolf A, Berkhout BJ, Stam HJ. Disturbance of the menstrual pattern after local injection with triamcinolone acetonide. Ann Rheum Dis. 1998; 57:700-4.




DOI: http://dx.doi.org/10.25759/spmfr.403

Apontamentos

  • Não há apontamentos.


Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Revista da Sociedade Portuguesa de Medicina Física e de Reabilitação